Bluebird Exceeds Expectations at ASH
Research - Bluebird Bio (BLUE) surprised everyone on Monday evening, exceeding expectations for early data from the LentiGlobin drug candidate.
Read NowResearch
High Fives All Around as Merck Takes Down Cubist
Research - Merck is buying Cubist for $102/share, valuing the antibiotics company at $9.5B including its cash. After the close on Monday, the U.S. District Court in Delaware … Continue Reading
Premium: Read Now
Checkpoint Inhibitors: What are They and One Compelling Small-Cap Player
Research - Immune checkpoint regulators are again making headlines, this time at the American Society of Hematology, where they are demonstrating exciting early efficacy in hematological malignancies. … Continue Reading
Read Now
A Short-term Chart Trade and Options Idea for this Upcoming Data Release
Research - This company has a data release coming imminently. We've outlined one equity, and one options strategy for the event.
Premium: Read Now
Trim this Position for an 18% Gain
Research - This thesis played out beautifully, and it's time to take some profit - 18% in just two weeks.
Premium: Read NowOn Bluebird Bio After a Glimpse at Preliminary Lentiglobin Data
Research - Last week, preliminary data for bluebird bio (BLUE)’s Lentiglobin were released as part of the abstract dump for ASH in December (we wrote at length about this, here). Bluebird … Continue Reading
Read NowTake Advantage of this Trading Channel Before Year-End
Research - In the relative near-term, XOMA Corporation (XOMA) is guiding to complete and release results from EYEGUARD-B, a phase III study of the company’s lead drug candidate gevokizumab … Continue Reading
Premium: Read Now